Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Small

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|November 3, 2018
Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipientsEmily M Eichenberger, Rosemary Soave, Dana Zappetti, et al.
Frontiers in Nephrology|September 7, 2023
Complications of rabbit anti-thymocyte globulin induction immunosuppression in HIV-infected kidney transplant recipientsAyman Al Jurdi, Esther C Liu, Thalia Salinas, et al.
Journal of Fungi (Basel, Switzerland)|February 7, 2020
Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant <i>Candida tropicalis</i>: An Emerging Threat to Immunocompromised Patients with Hematological MalignanciesMaroun M Sfeir, Cristina Jiménez-Ortigosa, Maria N Gamaletsou, et al.
Science (New York, N.Y.)|December 4, 1981
Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swineD G Kleid, D Yansura, B Small, et al.
Plos One|May 15, 2014
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialDavid A Wohl, Laveeza Bhatti, Catherine B Small, et al.
Antiviral Therapy|December 8, 2016
Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trialJuergen K Rockstroh, Frank Plonski, Meena Bansal, et al.
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Neurology|December 10, 2008
Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer diseaseR Duara, D A Loewenstein, E Potter, et al.
American Journal of Veterinary Research|March 1, 1985
Dose-response evaluation of a genetically engineered foot-and-mouth disease virus polypeptide immunogen in cattleP D McKercher, D M Moore, D O Morgan, et al.
HIV Clinical Trials|April 30, 2015
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agentsJuergen K Rockstroh, Vicente Soriano, Frank Plonski, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|November 3, 2018
Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipientsEmily M Eichenberger, Rosemary Soave, Dana Zappetti, et al.
Frontiers in Nephrology|September 7, 2023
Complications of rabbit anti-thymocyte globulin induction immunosuppression in HIV-infected kidney transplant recipientsAyman Al Jurdi, Esther C Liu, Thalia Salinas, et al.
Journal of Fungi (Basel, Switzerland)|February 7, 2020
Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant <i>Candida tropicalis</i>: An Emerging Threat to Immunocompromised Patients with Hematological MalignanciesMaroun M Sfeir, Cristina Jiménez-Ortigosa, Maria N Gamaletsou, et al.
Science (New York, N.Y.)|December 4, 1981
Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swineD G Kleid, D Yansura, B Small, et al.
Plos One|May 15, 2014
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialDavid A Wohl, Laveeza Bhatti, Catherine B Small, et al.
Antiviral Therapy|December 8, 2016
Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trialJuergen K Rockstroh, Frank Plonski, Meena Bansal, et al.
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Neurology|December 10, 2008
Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer diseaseR Duara, D A Loewenstein, E Potter, et al.
American Journal of Veterinary Research|March 1, 1985
Dose-response evaluation of a genetically engineered foot-and-mouth disease virus polypeptide immunogen in cattleP D McKercher, D M Moore, D O Morgan, et al.
HIV Clinical Trials|April 30, 2015
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agentsJuergen K Rockstroh, Vicente Soriano, Frank Plonski, et al.
Pageof 10